An Allergy Therapeutics (LON:AGY) breakthrough has the potential to protect against severe allergic reactions to peanuts, according to research carried by a leading academic journal.
The single injection helped mice generate “sustained immunity and protection through vaccination”, helping prevent anaphylaxis.
CFO Nick Wykeman and CEO Manuel Llobet are pretty excited about the firm's early stage study and have a strong cash base to work from.
The data from the firm’s early-stage study was carried in The Journal of Allergy and Clinical Immunology, or JACI for short.
The first clinical trials of the vaccine are expected to get underway over the summer.